Actuate to participate in lantern's pharma webinar on ai-driven drug development

Chicago and fort worth, texas, oct. 29, 2024 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), announced that it will participate in “ webinar wednesday ” hosted by lantern pharma on october 30, 2024.
ACTU Ratings Summary
ACTU Quant Ranking